• WELCOME TO
    AVANTGARDE UROLOGY
    Center of Minimally Invasive Surgery

Presentations in International Meetings

Congress Presentations:

  • Advances In Oncology. The expanding role of Octreotide. Noordwijk, Netherlands. (September 2001)
    1. Prostate cancer cell survival in bone metastasis and disease progression to androgen refractory stage: development of a novel endocrine manipulation for hormone refractory prostate cancer.
    Koutsilieris M., Mitsiades C., Sourla A., Sotiriou E., Tiblalexi D., Lembessis P., Dimopoulos T., Lambou T., Tsintavis A., Vacalikos J., Milathianakis C., Bogdanos J., Karamanolakis D., Kapsalis Z., Pliotas G., Dardoufas C.
    PUBLISHED ABSTRACT

  • 3rd Balkan Congress of Immunology – Athens (2001)
    2. Serum levels of EPO and TNFa in patients with prostate carcinoma and anemia, with lack of correlation between them.
    A. Chloraki-Mpompota, D. Karamanolakis, I. Mpogdanos, D. Lekakou, M. Paouri, K. Milathianakis, A. Tsintavis, E. Pagkalou-Thoua.

  • 13th European Annual Meeting of Paediatric Urology - Budapest (April 2002)
    3. Ureteropelvic junction obstruction due to crossing renal vessels: clinical and imaging features.
    A.Rigas, D. Karamanolakis, Ch. Mamoulakis, A. Stefanidis, P.A.  Androulakakis.
    PUBLISHED ABSTRACT in British Journal of Urology International, official Journal of the ESPU.

  • 21st Annual European Society for Therapeutic Radiology and Oncology (ESTRO) Meeting (Prague, September 2002)
    4. Effect of Aminofostine on toxicities associated with radiation therapy for localized prostate cancer.
    M. Synodinou-Menegaki, D. Antonadou, M. Bouphy, D. Karamanolakis, N. Biazis, K. Papatheodorou, D. Nikolakis, K. Milathianakis, N. Trouvalas.
    PUBLISHED ABSTRACT, No: P , in the relative suppl. of Journal of   European Society of Radiology and Oncology, Vol. 64, Supplement 1, September 2002, p:. Official Journal of the ESTRO.
    5. Radiotherapy for elderly patients with locally advanced bladder cancer supported with aminofostine.
    M. Bouphy, M. Synodinou-Menegaki, D. Antonadou, I. Mpogdanos, D. Karamanolakis, K. Milathianakis, M. Hristodoulidou, G. Sarris, N. Throuvalas.
    PUBLISHED ABSTRACT, No: P 1046, in the relative suppl. of Journal of European Society of Radiology and Oncology, Vol. 64, Supplement 1, September 2002, pp: 306. Official Journal of the ESTRO.

  • 26th Congress of the Société Internationale d’Urologie – Stockholm (September 2002)
    6. Penile metastases of transitional cell carcinoma of the bladder presenting as priapism. Report of two cases [Moderated Poster. Published abstract].
    D.K. Karamanolakis, K.N. Milathianakis, I.M. Mpogdanos, I. Michailidis, G.D. Becchini, M. Synodinou.
    PUBLISHED ABSTRACT, No: MP-3.4.12, British Journal of Urology International Vol 90- Supplement 2, September 2002, p: 113. Official Journal of SIU.
    7. Anemia associated with Hormone Refractory Prostate Carcinoma. Effects of Recombinant Human Epoetin-β [Moderated Poster. Published abstract].
    D.K. Karamanolakis, K.N. Milathianakis, I.M. Mpogdanos, P.B. Repousis, A. Chloraki-Bobota, H. Majed, E. Pagalou-Thoua, A.H. Tsintavis.
    PUBLISHED ABSTRACT, No: MP-5.1.10, British Journal of Urology International Vol 90- Supplement 2, September 2002, p: 181. Official Journal of SIU.

  • European Association of Nuclear Medicine Annual Congress – Vienna (September 2002)
    8. How useful Octreoscan is in hormone-refractory prostate cancer patients with osseous metastases.
    M. Koutsilieris, K. Milathianakis, J. Bogdanos, D. Karamanolakis, A. Stavraka, G.S. Limouris.
    PUBLISHED ANSTRACT in European Journal of Nuclear Medicine and Molecular Imaging, Abstract No: P 198, Vol 29, Supplement 1, August 2002, p:240. Official Journal of the European Association of Nuclear Medicine.

  • XVIIIth EAU Congress-Madrid, Spain (March 2003)
    9. The use of Zolendronic acid in painful osseous metastases due to prostate cancer. (Moderated Poster)
    Milathianakis C., Bogdanos J, Karamanolakis K D, Tsintavis A, Koutsilieris M.
    PUBLISHED ABSTRACT, Abstract No: MP 747, European Urology Vol. 2, Supplement 1, February 2003, p: 189. Official Journal of the EAU.

  • 8th Congress of the Mediterranean Association of Urology, Crete-Greece (September 2003)
    10. Treatment of BCG induced cystitis with intravescical instillation of GM-CSF growth-factor. (Oral Presentation).
    Milathianakis K.N, Karamanolakis D.K, Bogdanos J.M, Tsintavis A.H.
    11. The value of DNA analysis in transitional cell carcinoma of the bladder.
    Karamanolakis D.K, Alexia S., Milathianakis K.N, Bogdanos J,  Tsintavis A, Driva G. (Oral Presentation).
    12. Anti-Survival Factor (ASF) Therapy: a novel bone-targeted hormone manipulation for patients with androgen ablation refractory prostate cancer re-introduces clinical responsiveness to androgen ablation therapy. A multicentre research study. (Oral Presentation).
    Koutsilieris M, Mitsiades C, Bogdanos J, Lembessis P, Dimopoulos T, Zagaras E, Karamanolakis D.K, Milathianakis C, and Tsintavis A.
    13. Preliminary results of In-111 Pentetreotide (Octreoscan) scan in patients with hormone refractory prostate carcinoma and bone metastases, regarding the next-line therapeutic decision. (Oral Presentation).
    Bogdanos I.M., Karamanolakis D.K, Milathianakis K.N, Lymouris G, Koutsilieris M, Tsintavis A.H.

  • 15th Congress of the European Society of Pediatric Urology, Regensburg-Germany (21-24 April 2004)
    14. Myogenic bladder decompensation in boys with a history of posterior urethral valves is caused by secondary bladder neck dysfunction?
    Dimitrios K. Karamanolakis, Georgios Tsahouridis, Antonios A. Stefanidis, Philippos A. Androulakakis. [Moderated Poster].
    PUBLISHED ABSTRACT Volume 93, Issue 52, p64, British Journal of Urology International, Official Journal of ESPU.

  • 56th Congress of the German Urological Society (DGU), Rhein-Main-Hallen, Wiesbaden (22 – 25 September 2004)
    15. Dealing with BCG induced cystitis by intravesical instillation of GM-CSF Growth Factor.
    Dimitrios K. Karamanolakis,  Konstantinos N. Milathianakis, Ioannis M. Bogdanos    [Clinical Poster].

  • 98e Congrès Français d’Urologie (17-20 November 2004)
    16. Acceptabilité et evolution de l’incontinentation prothetique par protheses Memocath.
    Ruffion A, Karamanolakis D, Leriche A.
    PUBLISHED ABSTRACT Volume 14, Issue 5, Supplement 1, p5A, Progrès en Urologie, Official Journal of AFU.
    17. Evaluation de l’ echographie portable sur 100 patients en consultation d’ Urologie.
    Devonec M, Ruffion A, Lopez JG, Champetier D, Roumier X, Hoch M, Tajjour M, Karamanolakis D, Perrin P.
    PUBLISHED ABSTRACT Volume 14, Issue 5, Supplement 1, p13A, Progrès en Urologie, Official Journal of AFU.
    18. L’ IPSS peut-il être remplacé par une echelle analogique visuelle?
    Perrin P, Cucherat M, Karamanolakis D, Ruffion A.
    PUBLISHED ABSTRACT Volume 14, Issue 5, Supplement 1, p63A, Progrès en Urologie, Official Journal of AFU.

  • XXth EAU Congress-Istanbul, Turkey (16-19 March 2005)
    19. "What is the optimal dose of botulinum toxin-A Dysport in neurogenic detrusor overactivity? A dose-effect study.
    A. Ruffion [1], Y. Tanneau [2], A. Gignoux [1], S. Culem [1], D.Karamanolakis [1], B. Leriche [1], A. Leriche [1], P. Grise [2]
    [1] Centre Hospitalier Lyon Sud, Service Urologie, Lyon, France, [2]Centre Hospitalier Charles Nicolle, Service Urologie, Rouens, France.
    PUBLISHED ABSTRACT Volume, Issue, Supplement 2005, p, European Urology, Official Journal of EAU.

  • XXIth European Association of Urology Congress (Paris, 05-08 April 2006)
    20. Randomized controlled clinical trial of a combination of somatostatin analog and dexamethasone plus zoledronate vs zoledronate in patients with androgen ablation refractory prostate cancer. (moderated poster) CME: 5
    Koutsilieris M, Mitsiades C, Bogdanos J, Karamanolakis D, Milathianakis C, Sourla A, Dimopoulos T.
    PUBLISHED ABSTRACT Volume 5, Issue 2, Supplement 2006, p93, European Urology, Official Journal of EAU.

  • World Congress of EndoUrology, Cleveland-USA /08/2006)
    21. Laparoscopic transvesical adenomectomy for BPH in massive prostate glands.
    Dimitrios K Karamanolakis, Gordon Kooiman, Rajbabu Krishnamoorthy, Peter M. Thompson, Gordon Muir, H. Godbele, Philippe Grange.
    PUBLISHED ABSTRACT Volume 20, Supplement 1, 2006, p.272, Journal of Endourology, Official Journal of EndoUrological Society.

  • 12th International congress on Hormonal Steroids and Hormones &, Cancer (13-16 September 2006, Athens-Greece)
    22. Serum Testosterone: a potentially adjunct screening test for the assessement of the risk for prostate cancer among men with modestly elevated PSA values >,3.0 and ≤10ng/ml. Poster.
    DK Karamanolakis, T. Lambou, J. Bogdanos, C. Milathianakis, A. Sourla, P. Lembessis, A. Halapas, N. Pisssimissis, N. Dessypris, E.Th. Petridou, M. Koutsilieris.
    23. Reduction of bone resorption in elderly patients with metastatic hormone refractory prostate cancer (HRPC) – Initial Experience using Zolendronic Acid. Poster.
    L. Drudge-Coates, K. Rajbabu, D. Karamanolakis, GH Muir, K. Walsh, PM Thompson.
    24. Zolendronate monotherapy versus zolendronate plus somatostatin analog and dexamethasone in patients with stage D3 prostate cancer. Poster.
    J. Bogdanos, CS. Mitsiades, D. Karamanolakis, C. Milathianakis, A. Sourla, T. Dimopoulos, M. Koustilieris.
    25. Combination of somatostatin analog plus dexamethasone in stage D3 prostate cancer patients with bone metastases. Poster. AWARDED.
    J. Bogdanos, CS. Mitsiades, T. Dimopoulos, D. Karamanolakis, C. Milathianakis, A. Tsintavis, M. Koutsilieris.

  • 2nd South-Eastern European Meeting (SEEM) (Thessalonica-Greece 20-21/10/2006)
    26. Measurement of serum testosterone as potentially adjunct screening test for the assessment of the risk of prostate cancer amongst men with PSA values >,3.0 and ≤ 10ng/ml.
    DK Karamanolakis, Th. Lambou, J. Bogdanos, C. Milathianakis, A. Sourla, P. Lembessis, A. Halapas, N. Pissimissis, N. Desypris, E. Petridou, M. Koutsilieris. Moderated Poster.

  • Annual Meeting of the Hellenic and Italian Medical society of the United  Kingdom
    27. Early detection of Prostate Cancer with the introduction of the Testosterone.
    DK Karamanolakis.

  • Royal Society of Medicine: Section of Oncology / Sylvia Lawler Prize, 4th July 2007 – London, UK
    28. Serum Testosterone: a Potentially Adjunct Screening Test for the Assessment of the Risk for Prostate Cancer Amongst Men with Modestly Elevated PSA Values (>,3.0 and ≤10.0 ng/ml). Oral presentation.
    DK. Karamanolakis.

  • South Thames Regional Meeting (London 19/11/2008)
    29. Laparoscopic varicocele ligation in the management of chronic testicular pain. Oral presentation.
    CT Brown, Sharma D, Kouriefs C, Kooiman G, Karamanolakis D, Muir GH, Grange P
    30. Photoselective vaporization of the prostate using the KTP Greenlight laser for the treatment of bladder outflow obstruction in patients with bladder stones: one step treatment. Oral presentation.
    D Karamanolakis, ME Graziano, F Liberale, S Sellaturay, CT Brown, GH Muir
    31. Laparoscopic partial nephrectomy, no clamp no stopwatch technique. Oral presentation.
    W Lam, C Kouriefs, D Sharma, C Brown, M Arya, D Karamanolakis, G Kooiman, P Grange.

  • 24th Annual EAU Congress
    32. Laparoscopic partial nephrectomy, no clamp no stopwatch technique. Oral presentation.
    W Lam, C Kouriefs, D Sharma, C Brown, M Arya, D Karamanolakis, G Kooiman, P Grange.

  • 15th Annual Congress of Cryosurgery (St Petersburg, 1-4 October 2009)
    33. One step beyond conservative management of multiple renal tumors.
    C. Kouriefs, D. Sharma, CT. Brown, D. Karamanolakis, G. Kooiman, F. Lugnani, P. Grage. (Awarded as Best International Poster).
    34. Flexible-tip Laparoendoscopic Single Site (FLESS) solo surgeon cryotherapy of renal tumour. (Moderated Poster)
    C.Kouriefs, C.T.Brown, D.Sharma, D.Karamanolakis, G.Kooiman, P.Grange

  • World Congress on Men’s Health &, Gender (Vienna 9-11 October 2009)
    35. Measurement of serum testosterone as potentially adjunct screening test for the assessment of the risk of prostate cancer amongst men with PSA values >,3.0 and ≤10ng/ml.
    DK Karamanolakis, Th. Lambou, J. Bogdanos, C. Milathianakis, A. Sourla, P. Lembessis, A. Halapas, N. Pissimissis, N. Desypris, E. Petridou, M. Koutsilieris. (Moderated Poster).

  • 3rd World Congress of Controversies in Urology (Athens 25-28 February 2010)
    36. Measurement of serum testosterone as potentially adjunct screening test for the assessment of the risk of prostate cancer amongst men with PSA values >,3.0 and ≤10ng/ml.
    DK Karamanolakis, Th. Lambou, J. Bogdanos, C. Milathianakis, A. Sourla, P. Lembessis, A. Halapas, N. Pissimissis, N. Desypris, E. Petridou, M. Koutsilieris. (Moderated Poster).
    37. 3Dimentional pathological mapping biopsies of the prostate: our initial experience.
    DK Karamanolakis, S. Pomplun.
Attention! The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with your physician for further evaluation.

Send your reply